Colorectal Cancers from Distinct Ancestral Populations Show Variations in BRAF Mutation Frequency

• Megan C. Hanna,

  Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Broad Institute, Cambridge, Massachusetts, United States of America

  ⨯
• Christina Go,

  Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Christine Roden,

  Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Robert T. Jones,

  Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Panisa Pochanard,

  Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Ahmed Yasir Javed,

  Affiliation Boston Baskin Cancer Foundation, Baptist Cancer Center, Memphis, Tennessee, United States of America

  ⨯
• Awais Javed,

  Affiliation Boston Baskin Cancer Foundation, Baptist Cancer Center, Memphis, Tennessee, United States of America

  ⨯
• Chandrani Mondal,

  Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Emanuele Palescandolo,

  Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Paul Van Hummelen,

  Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Charles Hatton,

  Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Adam J. Bass,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Broad Institute, Cambridge, Massachusetts, United States of America

  ⨯
• Sung Min Chun,

  Affiliation Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea

  ⨯
• Deuk Chae Na,

  Affiliation Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea

  ⨯
• Tae-Im Kim,

  Affiliation Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea

  ⨯
• Se Jin Jang,

  Affiliation Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea

  ⨯
• Raymond U. Osarogiagbon,

  Affiliation Boston Baskin Cancer Foundation, Baptist Cancer Center, Memphis, Tennessee, United States of America

  ⨯
• William C. Hahn,

  Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Broad Institute, Cambridge, Massachusetts, United States of America

  ⨯
• Matthew Meyerson,

  Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Broad Institute, Cambridge, Massachusetts, United States of America

  ⨯
• Levi A. Garraway,

  Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Broad Institute, Cambridge, Massachusetts, United States of America

  ⨯
•  [ ... ],
• Laura E. MacConaill

  * E-mail: Laura_Macconaill@dfci.harvard.edu

  Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Broad Institute, Cambridge, Massachusetts, United States of America

  ⨯
• [ view all ]
• [ view less ]